Desjardins, A., Barboriak, D. P., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., … Vredenburgh, J. J. (2008). Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients. Journal of Clinical Oncology, 26(15_suppl), 2026–2026. https://doi.org/10.1200/jco.2008.26.15_suppl.2026

Desjardins, A., D. P. Barboriak, J. E. Herndon, J. Marcello, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, H. S. Friedman, and J. J. Vredenburgh. “Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2026–2026. https://doi.org/10.1200/jco.2008.26.15_suppl.2026.

Desjardins A, Barboriak DP, Herndon JE, Marcello J, Reardon DA, Quinn JA, et al. Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients. Journal of Clinical Oncology. 2008 May 20;26(15_suppl):2026–2026.

Desjardins, A., et al. “Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 2026–2026. Crossref, doi:10.1200/jco.2008.26.15_suppl.2026.

Desjardins A, Barboriak DP, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Friedman HS, Vredenburgh JJ. Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):2026–2026.